Margaret Johnson, MD
Pulmonary Disease · Jacksonville, FLNPI 1639169568
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,420 of the $5,554 with a category attached, or 97.6%. Insmed, Inc. accounts for 65.2% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2024 at $3,576 and has fallen 99.5% since, to $17 in 2025.
Across 8 payments — averaging $694.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insmed, Inc.$4K
- Paratek Pharmaceuticals, Inc.$1K
- Cipla USA Inc.$500
- Boehringer Ingelheim$54
- United Therapeutics Corporation$21
Across 203 payments — averaging $2077.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Insmed, Inc.$382K
- AstraZeneca$37K
- Boehringer Ingelheim International GmbH$3K
What the payments were for
- Consulting fees$5,42098%
- Food & beverage$801%
- Education$541%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insmed, Inc. | 4 | $3,620 |
| Paratek Pharmaceuticals, Inc. | 1 | $1,360 |
| Cipla USA Inc. | 1 | $500 |
| Boehringer Ingelheim | 1 | $54 |
| United Therapeutics Corporation | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUZYRA$1,360
- 2$500
How this compares
$5,554 in reported general payments places this provider in the 60th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 104 | $2,721,643 |
| CaystonAztreonam Lysine | 16 | $199,652 |
| ZenpepLipase/Protease/Amylase | 12 | $82,705 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 67 | $43,386 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $37,107 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $17,946 |
| Spiriva HandihalerTiotropium Bromide | 13 | $11,398 |
| Advair HfaFluticasone Propion/Salmeterol | 24 | $10,213 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $8,171 |
| Incruse ElliptaUmeclidinium Bromide | 20 | $6,829 |
| Wixela InhubFluticasone Propion/Salmeterol | 19 | $5,183 |
| Roflumilast | 11 | $4,744 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 21 | $3,474 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 98 | $2,999 |
| Mycophenolate Mofetil | 20 | $1,955 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Jacksonville
- Jennifer FultonJacksonville$665K
- Jose Soto SotoJacksonville$504K
- Jorge MalleaJacksonville$457K
- Abubakr BajwaJacksonville$414K
- Bryan HustaJacksonville$283K
- Sebastian Fernandez-BussyJacksonville$257K
- Peter NassarJacksonville$141K
- Charles BurgerJacksonville$124K
- Daniel WyzanJacksonville$100K
- David Abia TrujilloJacksonville$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.